Janssen to stop fulranumab development in osteoarthritis pain
pharmafile | April 1, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing | Amgen, Janssen
Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain.
The J&J company says the decision is based on “strategic portfolio prioritisation”, as opposed to concerns over the safety of the drug – which belongs to an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds.
Janssen is terminating its license with Amgen fulranumab and is returning all program rights back to Amgen. The two signed a licensing agreement in 2008.
Joel Levy
Related Content
Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …